Annexon, Inc. (ANNX) shares are gaining more than 29 percent on Tuesday morning trade after the company announced a positive results for a phase 3 trial of C1q blocking antibody ANX005 in Guillain-Barre Syndrome. The trial met its primary endpoint with ANX005 30 mg/kg with statistically significant improvement.
Currently, ANNX is at $5.99, up 30.26 percent from the previous close of $4.58, on a volume of 36,935,980.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.